Pharmaceutical

Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 

Novo Nordisk has entered a collaboration with The Broad Institute to detect drug targets for Type 2 diabetes and cardiometabolic diseases.

Sep 7, 2023 - 20:00
Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs 
Novo Nordisk has entered a collaboration with The Broad Institute to detect drug targets for Type 2 diabetes and cardiometabolic diseases.
Read the original article

Tags:

Previous Article

IMIDomics to license TNAX’s drug candidate for IMIDs

Next Article

Apollo Therapeutics secures $226.5m to advance pipeline programmes

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Newly launched Calluna raises $81m to advance monoclonal antibody pipeline

Newly launched Calluna raises $81m to advance monoclona...

Jan 23, 2024

Opinion: Listen: Sniffing out the power, and limits, of the placebo effect

Opinion: Listen: Sniffing out the power, and limits, of...

Nov 1, 2023

Super DC Vaccine by Shanghai Cell Therapy Group for Sol...

Oct 3, 2023